
EU Approves Gilead’s Trodelvy-Keytruda Combo for First-Line Breast Cancer: A New Era in Treatment and Market Implications
The EU approved Gilead's Trodelvy in combination with Merck's Keytruda for first-line breast cancer, a major regulatory win that expands Trodelvy's market and reinforces Keytruda's dominance. The approval is expected...























